What is HC Wainwright’s Forecast for MindWalk Q1 Earnings?

MindWalk Holdings Corp. (NASDAQ:HYFT) – HC Wainwright reduced their Q1 2027 earnings per share (EPS) estimates for shares of MindWalk in a research note issued on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.05) per share for the quarter, down from their prior estimate of ($0.04). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk’s Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.17) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $0.01 EPS.

Other research analysts have also recently issued reports about the stock. JonesTrading initiated coverage on shares of MindWalk in a report on Thursday, April 16th. They set a “buy” rating and a $5.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. Finally, Wall Street Zen cut shares of MindWalk from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Price Performance

NASDAQ HYFT opened at $1.44 on Monday. The business has a fifty day moving average price of $1.56. The company has a market cap of $67.26 million, a price-to-earnings ratio of -6.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.72 and a current ratio of 2.80. MindWalk has a 1 year low of $0.99 and a 1 year high of $3.25.

MindWalk (NASDAQ:HYFT) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $3.03 million for the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.

Institutional Investors Weigh In On MindWalk

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its stake in shares of MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after purchasing an additional 18,600 shares during the period. Jane Street Group LLC grew its position in MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after buying an additional 96,018 shares during the period. XTX Topco Ltd increased its holdings in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after buying an additional 44,331 shares during the last quarter. Bank of Montreal Can increased its holdings in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in MindWalk in the fourth quarter worth about $91,000. 6.70% of the stock is owned by hedge funds and other institutional investors.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.